Following the approval of the first phase clinical trial of the "Innovative Anti Tumor Drug" developed by EMICRO Biomedicine Company on November 16, 2023, it has received widespread attention from the media and society. With the spread and expansion of the news, it has attracted many investment and financing companies from inside and outside the province to visit and inspect, expressing their intention and action to deeply cooperate with EMICRO Company, and playing a supporting, vigorous and assisting role in the first phase clinical trials of innovative drugs.

     On November 29, 2023, Zeng Chuilan, Deputy Director of Investment at Beijing Qidi Holdings Co., Ltd., and Liu Cheng, Legal Representative of Guanying Investment Holdings (Shenzhen) Co., Ltd., visited Henan EMICRO Microbial Pharmaceutical Co., Ltd. for work visits on November 30, 2023. At the company, the guests and hosts had a friendly and pragmatic discussion. After listening to the "Investment and Financing Plan for Innovative Drug Inhibitor TM471-1 Project", the two executives of the investment and financing parties had in-depth exchanges on issues of concern such as the upcoming phase one clinical trial, corporate equity structure, productization progress, industry and corporate environment, and the expected listing time of the shares. Two investment executives expressed confidence in the innovative drug project of EMICRO Biomedicine and expressed their intention to cooperate.

　  图为：启迪控股股份有限公司投资副总监曾垂兰（右四）在观看、听取知微创新药情况介绍。

　  图为：冠瑛投资控股（深圳）有限公司高管刘成在座谈会上。